Sign in
Enrolling by invitationNo phase

Using wearable devices to track insulin-making cells in prediabetes and type 2 diabetes

Tests glucose monitors and the Oura Ring in adults with prediabetes or type 2 diabetes.

Key facts

Who runs it
4YouandMe
Where
San Francisco, United StatesSee the site
Trial code
Registry title
BETA: Study in Prediabetes Type 2 Diabetes
Status
Enrolling by invitation
People taking part
130 people, planned
Started
25 Mar 2026
Expected to end
1 Feb 2027
Type of study
Observational
Record updated
20 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with prediabetes or type 2 diabetes who live in the North San Francisco Bay area. They will wear a glucose monitor and a smart ring.

Age
18 years or older
Sex
All sexes can join
Disease stage
An established diagnosis of prediabetes or type 2 diabetes, with HbA1c below 8% (64 mmol/mol) and BMI between 18-40 kg/m2
Earlier treatment
If you use long-acting insulin, you take it at bedtime only. Your medicines must have at least 30 days of supply. No new medicine in the last 30 days. Weight stable (± 10 pounds (5 kg)) for 2 months.
Biomarker or test result
HbA1c below 8% (64 mmol/mol)

Main reasons for not taking part

  • Type 1 diabetes or MODY
  • Using an insulin pump or any Abbott CGM
  • Pregnant or breastfeeding
  • Using glucocorticoids, non-selective beta blockers or thiazide diuretics
  • Currently using tobacco products

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • 18+ years old
  • Have an established diagnosis of Prediabetes or Type 2 diabetes
  • Have a glycated hemoglobin (HbA1c) below 8% (64 mmol/mol) and a body mass index (BMI) between 18-40 kg/m2 that will be determined from your height and weight
  • Are willing to use an Abbott FreeStyle Libre 3/3+ Continuous Glucose Monitor (CGM) supplied by the study and provide the study investigators access to the CGM data
  • Are willing to use the study wearable devices (e.g., Oura Ring)
  • Are able to read, write, and speak in English
  • If you use long-acting insulin, you must be on a prescribed regimen where you administer it at bedtime only and no other time of day (bolus short-acting may be used at any time as needed)
  • All medication regimens must have a minimum of 30 days supply, and no new medications started within 30 days of enrollment
  • Weight must be stable (± 10 pounds) for 2 months prior to enrollment
  • Must have a personally owned iPhone 6s or newer (iOS 16.4+) or Android smartphone (version 12 or newer) and use this phone to download and use the study app and use the provided study devices
  • Must have a personally owned computer or tablet or have access to these devices at home
  • Must reside in the North San Francisco Bay area and be willing to travel to Novato, CA to attend two morning clinic assessments at the Buck Institute

Who cannot take part

  • Using any of the following medications: Glucocorticoids, Non-Selective Beta Blockers (e.g., propranolol), Thiazide Diuretics
  • Currently using tobacco products (cigarettes, vapes, chew, dip, etc.)
  • Dairy or soy allergy
  • Diagnosed with Type 1 diabetes or MODY (Maturity-Onset Diabetes of the Young)
  • History of pancreatic disease (other than diabetes) or pancreatic transplantation
  • Have any active malignancy within the last 12 months
  • History of bariatric / other gastrointestinal surgery anticipated to affect glucose metabolism / cause gastroparesis
  • History of systemic disease (hepatic, cardiovascular, other) likely to interfere with glucose metabolism or study participation
  • Using any Abbott CGM (prescribed or OTC)
  • BMI <18 kg/m2 or >40 kg/m2
  • Currently pregnant or breastfeeding
  • Using an insulin pump
  • Hospitalized overnight for any reason in the last 3 months

Where in United States

  • Buck Institute for Research on AgingSan Francisco, United StatesEnrolling by invitation

About the trial

What the trial wants to find out

This study is testing the feasibility of using non-invasive, remote digital tools including continuous glucose monitors (CGMs) and the Oura Ring to predict the function of beta-cells, the cells in the pancreas that secrete insulin. This study is being done in individuals with prediabetes or Type 2 diabetes. The aim is to develop remote digital tools that can predict the health and functioning of the pancreas in people with prediabetes or Type 2 diabetes, allowing personalized treatment approaches to preserve insulin secretion.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Beta-cell Evaluation Through Data-driven Assessments (BETA): Study in Prediabetes Type 2 Diabetes
Plain-language title
Using wearable devices to track insulin-making cells in prediabetes and type 2 diabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
20 May 2026